The FDA has withdrawn its approval for AstraZeneca’s corona drug Evusheld in the USA, sending the stock down. The British pharmaceutical company’s US-listed stocks fell 1.4 percent to $65.73.
The FDA said it was unlikely that the therapy would offer protection once morest the currently predominant Covid-19 variants such as Omicron. AstraZeneca has announced that the medicine will remain authorized in other regions such as the European Union and Japan.